MAPT and Alzheimer disease: Campbell et al. (2018) published a meta-analysis demonstrating that Metformin use in diabetic patients significantly lower the risk of dementia and AD. Sargramostin, an immunomodulator improved cognition and ameliorated Aß- and tau-pathology in AD patients, possibly via autophagy induction (Potter et al., 2021).